Enrollment has resumed, under a revised trial protocol, in the Phase 2b study GALACTIC-1, which is evaluating Galecto’s investigational inhaled therapy GB0139 in adults with idiopathic pulmonary fibrosis (IPF). Galecto in March had been advised to stop recruiting and treating certain trial participants after disparities were…
In February of 2016, I joined the Greater Kansas City Pulmonary Fibrosis Support Group. As I attended more meetings, I realized PF awareness was important, and I wanted to make a difference. Because I had a unique case of idiopathic pulmonary fibrosis (IPF) with ossification that excluded me from…
NeRRe Therapeutics has raised £20 million (nearly $28 million) to develop orvepitant as a treatment for the chronic cough that can impact quality of life for people with idiopathic pulmonary fibrosis (IPF). Orvepitant’s efficacy has been demonstrated in patients with refractory or unexplained chronic cough associated with reflex…
Researchers at the University of Alberta are studying whether combining a commercially available wearable device with artificial intelligence can effectively predict symptom worsening in people with chronic lung conditions, such as idiopathic pulmonary fibrosis (IPF). Developed by New York-based Health Care Originals to monitor asthma, the ADAMM-RSM…
With an emphasis on research and how well patients are living, the Pulmonary Fibrosis Foundation’s (PFF) PFF Summit 2021 is set to take place virtually Nov. 8–13. The global biennial pulmonary fibrosis (PF) conference, which is sponsored in part by Boehringer Ingelheim, will offer live, interactive educational…
Throughout their lives, many people experience an array of ups and downs. Days, months, or even years can be plagued with challenges that seem unfair. Conversely, people also can experience prolonged periods when things go well. Rare disease patients who frequently experience ups and downs caused by their illness know…
Alterations in the extracellular matrix — the network of molecules that surrounds and supports cells — and cell aging, a process of called senescence, both contribute to tissue scarring in idiopathic pulmonary fibrosis (IPF), according to a recent study. Yet, matrix changes do not lead to senescence, implying that…
My husband is retiring in a couple weeks. I’m not of retirement age, but sometimes life happens and decisions are forced upon us. (Photo by Ann Reynoso) My husband and I have quite an age gap. He is 16 years older than me, making our retirement stages uneven. While…
Gefapixant (MK-7264), an investigational cough suppressant, was safe and well-tolerated by patients with idiopathic pulmonary fibrosis (IPF), but did not significantly reduce chronic coughing, according to data from a Phase 2 clinical trial. Results from this trial were shared in the study, “Treatment of Persistent Cough in Subjects…
Four months of treatment with Tyvaso (inhaled treprostinil) significantly improved lung function in adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD), according to a post-hoc analysis of data from the Phase 2/3 INCREASE clinical trial. PH-ILD comprises a group of conditions characterized by significant lung scarring (fibrosis), including…
Get regular updates to your inbox.
